Effectiveness and safety of D/C/F/TAF in an observational Italian cohort: interim analysis of DIAMANTE (TMC114FD1HTX4011) study


1. National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS HIV/AIDS Department Roma, Italy; 2. 1st Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Milano, Italy; 3. Infectious diseases Unit, Papa Giovanni XIII Hospital, Bergamo, Italy; 4. Immunodeficiency and Gender related Infectious Diseases, AOU CRO, PO Policlinico G. whipping, Turin, Italy; 5. Immunodeficiency and Gender related Infectious Diseases, University of Milan, Italy; 6. A.O.O.R. Cologno Monza, Italy; 7. Divisione di Malattie Infettive Napoli, Italy; 8. Clinical Infectious Diseases, Department of System Medicine, Tor Vergata University, Rome, Italy; 9. Infectious Diseases Clinic, AOU Policlinico “P. Giaccone”, Palermo – Italy; 10. University of Sassari, Department of Medical, Surgical and Experimental Sciences, Unit of Infectious Diseases Sassari Italy; 11. IRCSS San Raffaele Scientific Institute, Department of Infectious Diseases, Milan, Italy; 12. Janssen-Cilag SpA, Medical Affairs Department, Infectious Diseases, Cologno Monza, Italy

To improve adherence to ART, a single-tablet regimen (STR) based on the cobicistat-boosted protease inhibitor darunavir (DRV), together with emtricitabine and tenofovir alafenamide (D/C/F/TAF), has been developed. This formulation reduces the pill burden and mistakes in drug intake.

BACKGROUND

MATERIALS AND METHODS

DIAMANTE is an Italian, retrospective and prospective observational study carried on HIV-positive adult outpatients treated with D/C/F/TAF in eighteen centers. Three groups of patients have been enrolled: Group 1 always treated with DRV-based ART; Group 2 patients switching to D/C/F/TAF from a non-DRV-based ART and Group 3 patients starting D/C/F/TAF as first-line therapy at least one month before enrollment (Figure 1). Here we show the results of an interim analysis related to the effectiveness and safety of D/C/F/TAF in patients who completed the study in August 2020.

RESULTS

Two-hundred-forty-six patients have been enrolled. Of them, 10% (25) were females. At the August 2020 analysis, including 187 patients having completed the study, the virological success was 97% in Group 1, 94% in Group 2 and 97% in Group 3 (Figure 2). It was noticed an improvement in all groups of the immunological outcome, especially in naïve patients who showed a median CD4 cell count increase of 15% at V4. The data are detailed in Table 1. At August 2020, 32/246 (13%) patients withdrew from the study; 5% for loss to follow up, 2% for stopping D/C/F/TAF-based treatment for any reason; 1% due to pregnancies and 3% for other reasons. Seventy-four out of 246 (30%) patients reported at least one AE of mild severity (78%); 3 (1%) patients discontinued the study due to AE. Twelve (5%) patients reported SAE, 3 of them discontinued study; one event was considered related to D/C/F/TAF.

CONCLUSIONS

Table 1 - Immunological Parameters stratified by groups

In the first 187 patients having completed the DIAMANTE study, the treatment based on D/C/F/TAF has shown to be effective and well-tolerated in clinical practice.

Acknowledgements:
Authors are grateful to all center and all patients participating in this study.

Funding:
DIAMANTE study was funded by Janssen-Cilag SpA, Italy